drugset / Trial / NCT03895788
A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
Open-label, cohort study to determine the safety and tolerability of the combination of daily niraparib and daily brivanib for one 28-day cycle in patients with advanced ovarian cancer.
Timeline
- Start
- 2019-01-14
- Primary completion
- 2019-12
- Completion
- 2020-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brivanib | Small molecule | 200 mg | — |
| Subject | Brivanib | Small molecule | 400 mg | — |
| Subject | Brivanib | Small molecule | 600 mg | — |
| Subject | Niraparib | Small molecule | 100 mg | — |
| Subject | Niraparib | Small molecule | 200 mg | — |